Key points are not available for this paper at this time.
Abstract Sclerobanding (SB) combines Rubber Band Ligation (RBL) with 3% Polidocanol Foam Sclerotherapy (PFS) for treating hemorrhoidal disease (HD). This study evaluated a modified SB (mSB) procedure's efficacy and safety for Grade II/III HD. We enrolled patients with Grade II/III HD who received RBL treatments from Jan-Dec 2021 and mSB treatments from Jan 2022-Feb 2023 at Ningbo Medical Center Lihuili Hospital. Primary outcomes included treatment failure rate and delayed bleeding (DB) incidence. Secondary outcomes reviewed postoperative complications like pain, swelling, anal edema, and bleeding grade variation. Long-term follow-up assessed HD Symptom Score (HDSS), Short Health Scale for HD (SHSHD), and Patient Satisfaction (PS). Among 307 patients, 162 received mSB and 125 had traditional RBL. Baseline characteristics were similar, except for anticoagulant history and hospital stay length (P < 0.05). The mSB group had no delayed major bleeding, unlike 5 cases in the RBL group. Recurrence (6.8% vs. 17.0%) and treatment failure rates (6.8% vs. 18.6%) were lower in the mSB group (P < 0.05). Postoperative complications were similar, but the mSB group showed better bleeding improvement by the 7th day (P < 0.05). One-year follow-up indicated no significant differences in HDSS, SHSHD, and PS. The mSB procedure reduces ligation sessions, lowers DB risk, and decreases treatment failure without increasing postoperative complications.
Wang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: